Sentences with phrase «rare blood cancer»

Recently a program at Mount Sinai noted the emergence of rare blood cancers among 9/11 first responders.

The Learning Collaborative (TLC) is a dedicated collaboration between the NIH Chemical Genomics Center (NCGC) and its Therapeutics for Rare and Neglected Diseases (TRND) program, The Leukemia & Lymphoma Society (LLS), and KUCC to discover and develop new drug therapies for rare blood cancers.

The biotech received Food and Drug Administration (FDA) approval for its drug to treat the rare blood cancer acute myeloid lymphoma (AML), which will be marketed as Idhifa, on Tuesday.

Novartis» experimental product, CTL019, is being recommended for children and young adults aged 3 to 25 who have hard - to - treat (or recurring) forms of the rare blood cancer B - cell acute lymphoblastic leukemia (ALL).

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

But while Takeda has had a U.S. subsidiary since 1998, the maker of blockbuster medications like the multiple myeloma (a rare blood cancer) drug Velcade has set its sights on stronger growth in America going forward, particularly in franchises like inflammatory bowel disease, major depressive disorder, diabetes, and gout.

According to Loncar, U.S. pharma giant Johnson & Johnson (jnj) and Danish biotech partner Genmab stood above their peers during the conference with stellar new data for Darzalex, a treatment for multiple myeloma (a rare blood cancer) that was first approved last year.

Geron's imetelstat, though, is the first to show clear signs of reduced disease activity and even drive the rare blood cancer into complete remission.

In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer.